-David T Curiel Researcher Activity Profile

Research Author Detailed Information 

David T Curiel Publication Rate By Year

David T Curiel has published 2 paper(s) in 2002, 1 paper(s) in 2004, 6 paper(s) in 2006, 44 paper(s) in 2007, 14 paper(s) in 2008, for a total of 67 research publications in total.

David T Dt Curiel Author Information

LAST NAME: curiel

FIRST NAME: David T

INITIALS: dt

AFFILIATION:

Papers

David T Curiel's Publication Record

1. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses. Year Published: 2007
Department of Medicine, Pathology, and Surgery, University of Alabama at Birmingham, Birmingham, Alabama 35291, USA.
2. A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway. Year Published: 2007
Division of Human Gene Therapy, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama 35294-2172, USA.
3. Melanoma differentiation associated gene-7 (mda-7)/IL-24: a 'magic bullet' for cancer therapy? Year Published: 2007
Columbia University Medical Center, Department of Urology, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA. ds2039@columbia.edu
4. New generation adenoviral vectors improve gene transfer by coxsackie and adenoviral receptor-independent cell entry. Year Published: 2002
Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
5. Cytoprotection of pancreatic islets before and early after transplantation using gene therapy. Year Published: 2002
Transplant Center and Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
6. Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus. Year Published: 2006
Division of Neurosurgery, The University of Chicago, MC 3026, Chicago, IL 60637, USA.
7. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. Year Published: 2006
Division of Human Gene Therapy, Department of Medicine, Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL 35291, USA.
8. Circumventing recombination events encountered with production of a clinical-grade adenoviral vector with a double-expression cassette. Year Published: 2006
Division of Human Gene Therapy, Gene Therapy Center, The University of Alabama at Birmingham, 901-19th Street, South, BMR2-502, 35249-2184, USA.
9. A novel class of vascular endothelial growth factor-responsive genes that require forkhead activity for expression. Year Published: 2006
Center for Vascular Biology Research, Department of Medicine, the Division of Molecular, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA. rabid@bidmc.harvard.edu
10. Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment. Year Published: 2006
Department of Biochemistry, 401 College St., Massey Cancer Center, Room 2-108, Box 980035, Virginia Commonwealth University, Richmond VA 23298-0035, USA.
11. MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo. Year Published: 2006
Department of Biochemistry, Virginia Commonwealth University, Richmond, Virginia 23298, USA.
12. Targeting lung cancer using an infectivity enhanced CXCR4-CRAd. Year Published: 2007
Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, AL 35291, USA.
13. Gene therapy: human germline genetic modifications--assessing the scientific, socioethical, and religious issues. Year Published: 2007
Division of Human Gene Therapy, Department of Medicine, Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL 35294-2172, USA.
14. Thermostability/infectivity defect caused by deletion of the core protein V gene in human adenovirus type 5 is rescued by thermo-selectable mutations in the core protein X precursor. Year Published: 2007
Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
15. Self-assembling nanoclusters in living systems: application for integrated photothermal nanodiagnostics and nanotherapy. Year Published: 2007
Philips Classic Laser Laboratories, the Arkansas Cancer Research Center, the University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. zharovvladimirp@uams.edu
16. Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model. Year Published: 2007
Division of Human Gene Therapy, Department of Medicine, The Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
17. A three-dimensional assay for measurement of viral-induced oncolysis. Year Published: 2007
Department of Pathology, University of Mississippi Medical Center, Jackson, MS, USA.
18. Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas. Year Published: 2007
Department of Urology, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
19. Evolving gene therapy approaches for osteosarcoma using viral vectors: review. Year Published: 2007
Department of Orthopedic Surgery, VU University Medical Center, Amsterdam, The Netherlands. ma.witlox@vumc.nl
20. Radiation-induced cell signaling: inside-out and outside-in. Year Published: 2007
Department of Biochemistry, Virginia Commonwealth University, 401 College Street, Box 980035, Richmond, VA 23298, USA.
21. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). Year Published: 2007
Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA. rocconi@uab.edu
22. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Year Published: 2007
Southern Research Institute, Birmingham, AL, USA.
23. Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus. Year Published: 2007
Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
24. Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Year Published: 2007
Lung Research Laboratory, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
25. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Year Published: 2007
Department of Biological Chemistry, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California, USA.
26. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Year Published: 2007
Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York 10032, USA.
27. Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models. Year Published: 2007
Department of Neurosurgery, VU University Medical Center, 1007 MB Amsterdam, The Netherlands.
28. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Year Published: 2007
Division of Neurosurgery, Department of Surgery, University of Chicago, Chicago, IL 60637, USA.
29. Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling. Year Published: 2007
Department of Biochemistry, Virginia Commonwealth University, Richmond, VA 23298-0035, USA.
30. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Year Published: 2007
Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, 901 19th Street South, BMR2 502, Birmingham, AL 35294-2172, USA.
31. Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells. Year Published: 2007
Division of Neurosurgery, The University of Chicago, Chicago, Illinois 60637, USA.
32. Direct selection of targeted adenovirus vectors by random peptide display on the fiber knob. Year Published: 2007
Genetics Division, National Cancer Center Research Institute, Tokyo, Japan.
33. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Year Published: 2007
Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA.
34. Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck. Year Published: 2007
Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
35. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Year Published: 2007
Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA. pbf1@columbia.edu
36. Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses. Year Published: 2007
Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
37. Melanoma differentiation associated gene-7/interleukin-24 reverses multidrug resistance in human colorectal cancer cells. Year Published: 2007
Departments of Pathology and Urology, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032. pbf1@columbia.edu.
38. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Year Published: 2007
Department of Biochemistry, Box 980035, Virginia Commonwealth University, Richmond, VA 23298-0035. pdent@vcu.edu.
39. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Year Published: 2007
Division of Neurosurgery, Department of Surgery, University of Chicago, Chicago, IL 60637, USA.
40. Direct selection of targeted adenovirus vectors by random peptide display on the fiber knob. Year Published: 2007
Genetics Division, National Cancer Center Research Institute, Tokyo, Japan.
41. Melanoma differentiation associated gene-7/interleukin-24 reverses multidrug resistance in human colorectal cancer cells. Year Published: 2007
Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA.
42. Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Year Published: 2007
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, 618 20th Street South, Old Hillman Building-Room 538, Birmingham, AL 35249-7333, USA.
43. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Year Published: 2007
Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA.
44. Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck. Year Published: 2007
Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
45. Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses. Year Published: 2007
Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
46. Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan. Year Published: 2008
1Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
47. Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Year Published: 2007
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, 618 20th Street South, Old Hillman Building-Room 538, Birmingham, AL 35249-7333, USA.
48. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Year Published: 2007
Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA. pbf1@columbia.edu
49. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Year Published: 2007
Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, 901 19th Street South, BMR2 502, Birmingham, AL 35294-2172, USA.
50. Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Year Published: 2007
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, 618 20th Street South, Old Hillman Building-Room 538, Birmingham, AL 35249-7333, USA.
51. Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan. Year Published: 2008
1Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
52. Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan. Year Published: 2008
Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
53. A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway. Year Published: 2007
Division of Human Gene Therapy, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama 35294-2172, USA.
54. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Year Published: 2007
Department of Biochemistry, Box 980035, Virginia Commonwealth University, Richmond, VA 23298-0035, USA.
55. Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells. Year Published: 2008
Centre for Biologics Research, Biologics and Genetic Therapies Directorate, HPFB, Health Canada, Ottawa, Ontario, Canada.
56. [Tumour-dependent replicating adenoviruses in the treatment of carcinomas] Year Published: 2004
Universitäts-Frauenklinik, Heinrich-Heine-Universität, Düsseldorf.
57. Melanoma differentiation associated gene-7/interleukin-24 reverses multidrug resistance in human colorectal cancer cells. Year Published: 2007
Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA.
58. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control. Year Published: 2008
Division of Human Gene Therapy, Departments of Medicine, Surgery, Pathology and the Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL, 35294-2172, USA.
59. Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan. Year Published: 2008
Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
60. Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Year Published: 2008
Department of Biochemistry, Virginia Commonwealth University, 401 College Street, Massey Cancer Center, Box 980035, Richmond, VA 23298-0035. pdent@vcu.edu.
61. Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling. Year Published: 2008
Department of Biochemistry, Virginia Commonwealth University, 401 College Street, Massey Cancer Center, Box 980035, Richmond, VA 23298-0035. pdent@vcu.edu.
62. PERK-dependent regulation of HSP70 expression and the regulation of autophagy. Year Published: 2008
Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia, USA.
63. Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Year Published: 2008
Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
64. Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Year Published: 2008
Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
65. An adenoviral platform for selective self-assembly and targeted delivery of nanoparticles. Year Published: 2008
Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
66. Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. Year Published: 2008
Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA.
67. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Year Published: 2008
Department of Biochemistry, 401 College Street, Massey Cancer Center, Room 280a, Box 980035, Virginia Commonwealth University, Richmond, VA 23298-0035, USA.